Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages 3792-3799

  Romond, Edward H ^a,e   Jeong, Jong Hyeon ^a,b   Rastogi, Priya ^a,c   Swain, Sandra M ^a,f   Geyer, Charles E ^a,g   Ewer, Michael S ^h   Rathi, Vikas ⁱ   Fehrenbacher, Louis ^a,j   Brufsky, Adam ^a,c   Azar, Catherine A ^a,k   Flynn, Patrick J ^a,l   Zapas, John L ^a,m   Polikoff, Jonathan ^a,j   Gross, Howard M ^a,n   Biggs, David D ^a,p   Atkins, James N ^a,q   Tan Chiu, Elizabeth ^r   Zheng, Ping ^a,b   Yothers, Greg ^a,b   Mamounas, Eleftherios P ^a,o   Wolmark, Norman ^a,d   more..

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f WASHINGTON CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ Bon Secours Health System   (United States)

^j KAISER PERMANENTE   (United States)

^k San Diego ^*  (United States)

^l Metro Minnesota Ccop   (United States)

^m Franklin Square Hospital Center   (United States)

ⁿ CCOP   (United States)

^o AULTMAN HOSPITAL   (United States)

^p CHRISTIANA CARE HEALTH SYSTEM   (United States)

^q CCOP Southeast Cancer Control Consortium   (United States)

^r Florida Cancer Research Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CARDIAC DYSFUNCTION; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; STATISTICAL MODEL; TREATMENT OUTCOME;

EID: 84869125207     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.0010     Document Type: Article

References (22)

1. Piccart-Gebhart MJ, Proctor M, Leyland- Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
2. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005 (Pubitemid 41464706)
3. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
4. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
5. van Royen N, Jaffe CC, Krumholz HM, et al: Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 77:843-850, 1996 (Pubitemid 26143494)
6. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980
7. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
8. Jeong JH, Fine JP: Parametric regression on cumulative incidence function. Biostatistics 8:184-196, 2007
9. Harrell FE, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests. JAMA 247:2543-2546, 1982 (Pubitemid 12155954)
10. Bonetti M, Gelber RD: A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19: 2595-2609, 2000
11. Harrell FE, Lee KL, Mark DB: Multivariate prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996 (Pubitemid 26072233)
12. Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
13. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
14. Procter M, Suter TM, de Azambuja E, et al: Longer-term assessment of trastuzumab-related cardiac events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28:3422-3428, 2010
15. Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomized control trial. Lancet Oncol 12:236-244, 2011
16. Telli ML, Hunt SA, Carlson RW, et al: Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 25:3525-3533, 2007 (Pubitemid 47310891)
17. Ewer M, Lippman S: Type II chemotherapyrelated cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23:2900-2902, 2005 (Pubitemid 46224107)
18. Ewer M: The anthracycline-trastuzumab interaction: Upregulated binding may provide vital mechanistic insight. Eur J Cancer 43:2024-2025, 2007
19. Cardinale D, Colombo A, Torrisi R, et al: Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910-3916, 2010
20. Morris PG, Chen C, Steingart R, et al: Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 17:3490-3499, 2011
21. Du XL, Xia R, Burau K: Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol 28:S80-S90, 2011 (suppl)
22. Pinder MC, Duan Z, Goodman JS, et al: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815, 2007 (Pubitemid 47477254)